Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Applied StemCell, founded in 2008 and headquartered in Milpitas, California, is a leading company in the field of gene editing and induced pluripotent stem cell (iPSC) manufacturing. We specialize in providing a range of services, including the production of iPSC-derived products for gene and cell therapy research and development, the development of immune-compatible master iPS cell lines, and the delivery of large DNA fragments to pluripotent cells.
Since its inception, Applied StemCell has made significant strides in the biotechnology industry, contributing to advancements in stem cell research and gene therapy. The company has raised a total of $25.02 million in funding, demonstrating investor confidence in its potential and innovative approach to stem cell technology.
While there is currently no concrete information available regarding Applied StemCell's IPO prospects, the company's progress in the rapidly evolving field of stem cell research and gene editing could potentially make it an attractive investment opportunity in the future. However, it's important to note that any discussions about a potential Applied StemCell IPO or the possibility to buy Applied StemCell shares remain speculative at this time.
Factors that may influence any future IPO decision could include the company's financial performance, market conditions in the biotechnology sector, and the overall state of the IPO market. As with any potential investment, it's crucial for interested parties to conduct thorough research and consider multiple factors before making any investment decisions related to Applied StemCell or its potential stock.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Applied StemCell's IPO prospects remain uncertain, investors eager to explore opportunities in the biotechnology and stem cell research space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotech industry, including companies like Applied StemCell, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth and innovation in the stem cell sector before these companies hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
